Trend — Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg (J9394) in Medicare, the United States

The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.

The compound annual growth for J9394 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.